Rituximab in the treatment of high responding inhibitors in severe haemophilia A

  • Moschovi M
  • Aronis S
  • Trimis G
 et al. 
  • 7

    Readers

    Mendeley users who have this article in their library.
  • 17

    Citations

    Citations of this article.

Abstract

The development of antibodies to factor VIII (FVIII) in severely affected haemophilia A patients is a serious complication associated with increased morbidity and mortality. Bypassing agents are used to treat acute bleeding episodes; however, elimination of the inhibitors can only be achieved with immune tolerance therapy (ITT) in 60-80% of cases. High responding (HR) inhibitors are more likely to respond to ITT if the titre is decreased to

Author-supplied keywords

  • Children
  • High responding inhibitors
  • Immune tolerance therapy
  • Quality of life
  • Rituximab(anti-CD20)
  • Severe haemophilia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • M. Moschovi

  • S. Aronis

  • Georgios Trimis

  • H. Platokouki

  • K. Salavoura

  • F. Tzortzatou-Stathopoulou

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free